Oncology: carg-2020
| IL-12 | Amplify anti cancer immune response by inducing T cells |
|---|---|
| IL-17R antagonist | Expand immune response by bocking tumor-promoting IL-17RA and its markers |
| shRNA-PD-L1 | Sustain anti-cancer immunity by blocking immune checkpoint pathway PD-L1 preventing T cell exhaustion |
CARG-2020: Prevention of Tumor Recurrence; Potential Cure for Solid Tumors